Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy [Yahoo! Finance]
Biogen Inc. (BIIB)
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
biogen.com/en_us/investors.html
Company Research
Source: Yahoo! Finance
Salanersen is a novel antisense oligonucleotide and has the potential to deliver high efficacy in SMA with once-yearly dosing Biogen also debuted the design of the Phase 3 salanersen clinical trial program which is being initiated at sites around the world CAMBRIDGE, Mass., March 11, 2026 (GLOBE NEWSWIRE) Biogen Inc. (Nasdaq: BIIB) presented additional results from the Phase 1b study of salanersen, an investigational novel antisense oligonucleotide (ASO) given once a year for spinal muscular atrophy (SMA), at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The study evaluated salanersen in children who had suboptimal clinical status despite prior administration of gene therapy (onasemnogene abeparvovec-xioi). Salanersen was generally well-tolerated. Participants experienced a slowing of neurodegeneration and functional improvement, including achievement of new World Health Organization (WHO) motor milestones, following initiation of salanersen. The
Show less
Read more
Impact Snapshot
Event Time:
BIIB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIIB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
News
- Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference [Yahoo! Finance]Yahoo! Finance
- Biogen Stock: Is BIIB Outperforming the Healthcare Sector? [Yahoo! Finance]Yahoo! Finance
- Here's Why Biogen Inc. (BIIB) is a Strong Value Stock [Yahoo! Finance]Yahoo! Finance
- Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene TherapyGlobeNewswire
- Aduhelm (Biogen, Eisai) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]Yahoo! Finance
BIIB
Earnings
- 2/9/26 - Beat
BIIB
Sec Filings
- 3/11/26 - Form 8-K
- 2/17/26 - Form 4
- 2/17/26 - Form 4
- BIIB's page on the SEC website